Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Curcumin, a polyphenolic compound derived from , has gained significant attention as a potential anticancer agent due to its anti-inflammatory, antioxidant, and antitumor properties. Despite its therapeutic potential, the clinical application of curcumin is limited by its poor aqueous solubility, rapid metabolism, and limited bioavailability. To address these limitations, various nanomaterial-based encapsulation strategies have been developed, including polymeric nanoparticles, liposomes, solid lipid nanoparticles, micelles, dendrimers, and hybrid nanomaterials. These formulations aim to improve curcumin's solubility, stability, cellular uptake, and controlled release, thereby enhancing its targeted delivery to tumor sites. Such approaches not only reduce systemic toxicity but also improve therapeutic efficacy. Recent studies demonstrate that curcumin-loaded nanocarriers exhibit enhanced antitumor effects, selective cytotoxicity toward cancer cells, and minimized side effects. However, challenges such as achieving tissue specificity, evaluating potential toxicity, and the need for thorough clinical validation persist. Future research should prioritize the development of tissue-specific delivery systems, assess safety profiles, and ensure biocompatibility to optimize curcumin's clinical efficacy. This review provides an overview of the latest advancements in curcumin nanocapsules, critically comparing their advantages and limitations in cancer therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198038PMC
http://dx.doi.org/10.1016/j.mtbio.2025.101963DOI Listing

Publication Analysis

Top Keywords

cancer therapy
8
nanomaterial-based encapsulation
8
encapsulation strategies
8
advancing cancer
4
therapy nanomaterial-based
4
strategies enhanced
4
enhanced delivery
4
delivery efficacy
4
curcumin
4
efficacy curcumin
4

Similar Publications

Background: With the availability of more advanced and effective treatments, life expectancy has improved among patients with metastatic breast cancer (MBC), but this makes communication with their medical oncologist more complex. Some patients struggle to learn about their therapeutic options and to understand and articulate their preferences. Mobile health (mHealth) apps can enhance patient-provider communication, playing a crucial role in the diagnosis, treatment, quality of life, and outcomes for patients living with MBC.

View Article and Find Full Text PDF

Background: Colorectal cancer (CRC) risk models routinely adjust for endoscopic screening because of a) possible confounding with other risk factors and b) possible alteration of natural history of the disease due to adenoma detection and removal.

Methods: In this study, we defined a subject as screen-covered (SC) if a colonoscopy was performed in the past 10 years, and not screen-covered (NSC) otherwise. We created CRC risk models separately for SC and NSC subjects (HRSC, HRNSC) and then obtained a screening-coverage adjusted HR estimate (HRfull) based on a weighted average of ln(HRSC) and ln(HRNSC) with weight equal to the proportion of SC person-time in the NHS population.

View Article and Find Full Text PDF

Despite significant advancements in the treatment of non-small cell lung cancer (NSCLC) using conventional therapeutic methods, drug resistance remains a major factor contributing to disease recurrence. In this study, we aimed to explore the potential benefits of combining PI3K inhibition with Cisplatin in the context of NSCLC-derived A549 cells. Human non-small cell lung cancer A549 cells were cultured and treated with BKM120, cisplatin, or their combination.

View Article and Find Full Text PDF

Metastatic involvement (MB) of the breast from extramammary malignancies is rare, with an incidence of 0.09-1.3% of all breast malignancies.

View Article and Find Full Text PDF

Background: Standard treatment for glioblastoma includes chemotherapy, alkylating agents such as temozolomide (TMZ); however, MGMT resistance leads to recurrence. Demethoxycurcumin (DMC) has been reported to inhibit cancer cell growth, induce apoptosis, and prevent metastasis in different cancer models. We investigated the DMC-induced apoptosis and autophagy via inhibition of the AKT/mTOR pathway in human glioma U87MG and T98G cell lines.

View Article and Find Full Text PDF